We are Butterfly Therapeutics

Request a demo

Butterfly Therapeutics designs, develops, and clinically evaluates digital therapies, protocolized solutions dedicated to the management and treatment of pain. These solutions, tailored to healthcare practices and beneficial for patients, leverage technologies and the potential of neuropsychology.

2023

  • Signing a partnership with Viatris for exclusive promotion to hospitals and clinics of Bliss DTx in France.
  • Resumption of activities related to Lucine and the Endocare solution dedicated to endometriosis.
  • Public Prize for Bliss DTx during the Chirurgie 4.0 event of the National Academy of Surgery.

2022

  • L’effet Papillon becomes Butterfly Therapeutics.

2021

  • Publication and presentation of positive results from the REVEH study at the American Society of Clinical Oncology (ASCO) congress.

2019

  • Bliss receives the Innovation HIT Trophy at the FHF (Fédération Hospitalière de France/Hospital Federation of France) exhibition in the Treatment and Therapeutic Education category.
  • Dedication by the Muse band to Mélanie PERON(founder) before performing the song Bliss during their concert at the Stade de France in front of 72,000 people.
  • Bliss transforms into Bliss DTx.

2018

  • Completion of the first Bliss Universe.
  • Commercial launch of Bliss in its initial version (Samsung Gear VR).
  • Initiation of the multicenter randomized REVEH study dedicated to osteomedullary biopsies with Dr. Katell Le Dû.

2016

  • Initial trials of Bliss on voluntary patients (bone marrow aspiration, bone marrow biopsy, lumbar puncture, installation of a Port-A-Cath).

2014

  • Launch of the Papillon study, which will later be the subject of presentations at AFSOS (Association Francophone pour les Soins Oncologiques de Support) and SFAR (Société Française d’Anesthésie et de Réanimation).

2012

  • Establishment of the first scientific committee.

2011

  • Establishment of the company L’Effet Papillon in Laval, Mayenne (53) by Mélanie PERON.
  • First prototype of Bliss presented at the Laval Virtual 2011 exhibition.

2022

  • L’Effet Papillon becomes Butterfly Therapeutics.

2019

  • Bliss receives the Innovation HIT Trophy at the FHF (Fédération Hospitalière de France/Hospital Federation of France) exhibition in the Treatment and Therapeutic Education category.
  • Dedication by the Muse band to Mélanie PERON(founder) before performing the song Bliss during their concert at the Stade de France in front of 72,000 people.
  • Bliss becomes Bliss DTx.

2016

  • Initial trials of Bliss on voluntary patients (bone marrow aspiration, bone marrow biopsy, lumbar puncture, installation of a Port-A-Cath).

2012

  • Establishment of the first scientific committee.